CEP72 and acute lymphoblastic leukemia: Emerging evidence also links additional genetic variants to toxicities associated with other key agents used in ALL treatment regimens, including variants in <i>SLCO1B1</i> associated with methotrexate-related gastrointestinal toxicity and variants in <i>CEP72</i> associated with vincristine-induced neuropathy.